Table 2.

Univariate analysis of associations between SLC7A5/SLC3A2 co-expression in ER+/HER2− breast cancer of the Nottingham cohort.

SLC7A5−SLC3A2− vs	Outcome	Hazard Ratio	95% Confidence Interval	p	p *
SLC7A5+SLC3A2−	Recurrence	1.3	0.8–2.0	0.239	0.4
	Distant metastasis	1.4	0.8–2.4	0.147	0.2
	Survival	1.6	0.9–3.0	0.106	0.2
SLC7A5−SLC3A2+	Recurrence	0.9	0.7–1.2	0.720	0.9
	Distant metastasis	1.0	0.7–1.3	0.821	1.0
	Survival	1.1	0.8–1.6	0.289	0.3
SLC7A5+SLC3A2+	Recurrence	1.7	1.2–2.5	0.002	0.008
	Distant metastasis	2.4	1.6–3.5	0.000004	<0.0001
	Survival	3.2	2.0–4.9	1.0 × 10−7	<0.0001

p *: Adjusted p value.